Abstract
Background
Vaccination against the severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2) virus is recommended in multiple sclerosis (MS) to reduce the risk of complications from Coronavirus disease 2019 (COVID-19) infection. These vaccines were not investigated in people with MS (PWMS).
Objective
This study aimed to report the short-term safety of the COVID-19 vaccines among PWMS.
Methods
Pfizer-BioNTech mRNA (BNT162b2) vaccine and Oxford-Astra Zenecaa chimpanzee adenovirus-vectored (ChAdOx1 nCoV-19) vaccine have been approved to be used in Kuwait since December 2021. PWMS registered in Kuwait national registry were contacted by phone, WhatsApp, or through face-to-face interviews and were invited to complete our questionnaire. Demographic, clinical data, symptoms following the vaccine, worsening of pre-existing MS symptoms, and occurrence of relapse were recorded.
Results
Of the 820 PWMS, 647 completed the questionnaire. Between January 2021 and 31 August 2021, 383 (59.28%) PWMS received at least one dose of the approved vaccinations versus 63.4% of the general population on the same date. Their mean age was 36.82 + 8.80, and most of them, 247 (64.3%), were females. A total of 356 vaccinated cohorts (92.6%) were treated with disease-modifying therapies. Adverse events were reported by 261 (68.15%) subjects. One case of COVID-19 infection was encountered after the first dose of the BNT162b2 vaccine. Twenty-one (5.48%) cases reported worsening of pre-existing MS symptoms after the vaccine. Five patients (1.31%) reported relapse after the COVID-19 vaccine. The most common adverse events of the COVID-19 vaccine were pain at the injection site, fatigue, low-grade fever, and body ache; and resolved within one week. There was no significant association between use of disease modifying therapy (DMT) and COVID-19 vaccine adverse events.
Conclusion
BNT162b2 and ChAdOx1 nCoV-19 are safe for PWMS. No increased risk of relapse activity or worsening of pre-existing MS symptoms.
【저자키워드】 COVID-19, vaccination, multiple sclerosis, Kuwait, 【초록키워드】 SARS-CoV-2, Coronavirus disease 2019, Vaccine, BNT162b2 vaccine, coronavirus, COVID-19 vaccine, therapy, fatigue, Infection, risk, Symptom, virus, Symptoms, BNT162b2, adverse events, Cohort, COVID-19 infection, mRNA, Fever, Patient, Pain, Complication, age, General population, demographic, disease, questionnaire, Pfizer-BioNTech, ChAdOx1 nCoV-19, Therapies, association, dose, Safe, acute respiratory syndrome, Adverse, increased risk, Clinical data, first dose, worsening, Registered, injection, National, Complete, WhatsApp, females, objective, event, Occurrence, Result, reported, investigated, approved, treated, subjects, reduce, the vaccine, resolved, were recorded, common adverse event, 【제목키워드】 COVID-19 vaccination,